This Article Full Text (PDF) All Versions of this Article: 0269881106075275v1 21/5/553    most recent References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Lang, U. E. Articles by FeLber, W. Search for Related Content PubMed PubMed Citation Articles by Lang, U. E. Articles by FeLber, W. Social Bookmarking                         What's this?

Charles Bonnet Syndrome: successful treatment of visual hallucinations due to vision loss with selective serotonin reuptake inhibitors

Department of Psychiatry, University of Dresden, Dresden, Germany, undine.lang{at}gmx.de

Dariusz Stogowski

Department of Psychiatry, University of Dresden, Dresden, Germany

Doreen Schulze

Department of Psychiatry, University of Dresden, Dresden, Germany

Markus Domula

Department of Psychiatry, University of Dresden, Dresden, Germany

Eckart Schmidt

Department of Ophthalmology, University of Dresden, Dresden, Germany

Jüergen GaLLinat

Psychiatric Department, Charité University Medicine, Campus Mitte, Germany

Sems Malte Tugtekin

Department of Cardiac Surgery, Heart Centre Dresden, Dresden, Germany

Werner FeLber

Department of Psychiatry, University of Dresden, Dresden, Germany

Visual hallucinations are a common and often distressing consequence of vision loss, particularly in age-related macular degeneration. CharLes Bonnet Syndrome (CBS) is defined by the triad of complex visual hallucinations, ocular pathology causing visual deterioration and preserved cognitive status. So far, although this condition is frequent, no established treatment for CBS has been stated. We report here the case of a 78-year-old woman, who came in our hospital because of a 4-week long mild depressive symptomatology. For 1 year she experienced daiLy sudden, unexpected, vivid and elaborate hallucinations. Insight was completely present, so the patient stated that the hallucinations were unreal and that the faces, geometrical figures and animals she saw every day were possibly due to her vision loss. The Mini Mental State Examination, digit span and verbal fluency were administered and no cognitive impairment was reported. The visual acuity was hand motion. After 4 days of treatment with venLafaxine the hallucinations compLetely disappeared. This is the first case to show that selective serotonin (and noradrenalin) reuptake inhibitors may be an effective and well-tolerated treatment for visual hallucinations associated with vision loss, and it adds to evidence implicating serotonergic pathways in the pathogenesis of visual hallucinations.

Key Words: serotonin • Charles Bonnet Syndrome • CBS • hallucinations • epileptic • SSRI • venlafaxine • escitaopram

This version was published on July 1, 2007

Journal of Psychopharmacology, Vol. 21, No. 5, 553-555 (2007)
DOI: 10.1177/0269881106075275


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M.L. Jackson and J. Ferencz Charles Bonnet syndrome: visual loss and hallucinations Can. Med. Assoc. J., August 4, 2009; 181(3-4): 175 - 176. [Full Text] [PDF]